Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Largest global psoriasis survey shows 84% of people face discrimination and humiliation because of their skin | ||||||||||||||||||||||||||||||||||
By: Nasdaq / GlobeNewswire - 29 Jun 2016 | Back to overview list |
|||||||||||||||||||||||||||||||||
The digital press release with multimedia content can be accessed here:
"Novartis thanks all the participants who took part in this important survey. The only way we can improve patients' lives is to listen to them and work with the community to challenge the status quo," said Vasant Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. "This survey marks our commitment to support the World Health Organization's (WHO) resolution to make psoriasis a global health priority, fighting the stigma and ignorance associated with psoriasis and advancing patient care." Over 8,300 people from 31 countries took part in the survey, and it is also the first of its kind to explore perceptions of clear skin in psoriasis. This is the largest ever partnership between Novartis and patient organizations, including 25 groups from around the world. Along with unacceptable levels of discrimination and humiliation, the survey shows that nearly half (45%) of people with psoriasis have been asked if they are contagious[1]. The devastating effect psoriasis can have on personal lives and people's mental health was also revealed, with the survey showing 16% of people admit to hiding themselves away from the world as a coping mechanism[1]. This lack of hope and self-esteem is reflected in the results, with 55% of people stating they do not believe clear or almost clear skin is a realistic goal for them[1]. "Everyone deserves the right to receive effective treatment for their psoriasis and work towards the goal of clear skin, but this survey shows the majority of people simply don't think it's possible," said Dr. Richard B Warren, Reader Lecturer and Honorary Consultant Dermatologist at the Dermatology Centre Salford Royal Foundation Hospital, University of Manchester. "Though we may not be able to change the public's attitude overnight, as dermatologists, we should work with patients to encourage them to strive towards a treatment goal of clear skin." Further survey results and a new thought provoking video from body paint artist Natalie Fletcher can be found on www.skintolivein.com , an online hub from Novartis with social media channels across Facebook , Twitter , YouTube and Instagram , that is dedicated to educating and supporting patients with severe skin conditions, such as psoriasis. Findings from the survey are also being prepared for submission to scientific journals and will be presented at the 25 th European Association of Dermatology and Venereology (EADV) Congress.
About psoriasis
About the survey
Participants in the survey come from the following 31 countries: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Denmark, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, the Netherlands, Norway, Portugal, Romania, Russia, South Korea, Sweden, Switzerland, Taiwan, Turkey, the UK and the US.
Disclaimer
About Novartis
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis .
References
# # # Novartis Media Relations
e-mail: media.relations@novartis.com Novartis Investor Relations
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Novartis International AG via GlobeNewswire
HUG#2023707
|
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
Copyright 2016 Nasdaq / GlobeNewswire | Back to overview list |